Generic Cymbalta & Duloxetine Cancer Lawsuit Lawyers

Duloxetine Recall Lawsuit Investigation: More Than 350,000 Bottles Recalled Over Potential Cancer-Causing Nitrosamine Impurity

What Parker Waichman LLP Found

• More than 350,000 bottles of duloxetine delayed-release capsules have been recalled due to N-nitroso-duloxetine levels above FDA-recommended limits.
• The affected medication is generic Cymbalta distributed by Breckenridge Pharmaceutical and manufactured by Towa Pharmaceutical Europe.
• The FDA classified the recall as Class II.
• Nitrosamine exposure above acceptable limits over long periods may increase cancer risk.
• Patients should not stop duloxetine abruptly without speaking with a doctor or pharmacist.

A major recall involving duloxetine delayed-release capsules has raised concerns for patients across the United States who rely on the medication for depression, anxiety, fibromyalgia, diabetic nerve pain, and chronic pain conditions. Duloxetine is the generic form of Cymbalta and is widely prescribed to help patients manage serious medical and mental health conditions. When a medication used daily by thousands of patients is recalled because of a potential cancer-related impurity, consumers deserve clear information about what happened, what products are affected, and what legal rights may exist if harm occurs.

The recall involves certain lots of duloxetine delayed-release capsules manufactured by Towa Pharmaceutical Europe and distributed by Breckenridge Pharmaceutical, Inc. The concern involves N-nitroso-duloxetine, a nitrosamine drug substance-related impurity found above FDA-recommended limits. Nitrosamines are chemical compounds that may increase cancer risk when people are exposed to them above acceptable levels over long periods of time.

According to public recall reports, more than 350,000 bottles of duloxetine are affected. The recalled products include 30 mg and 60 mg delayed-release capsules packaged in 90-count and 1,000-count bottles. The FDA classified the recall as Class II, which means use of or exposure to the recalled product may cause temporary or medically reversible health consequences, or that the probability of serious health consequences is remote.

Patients should not abruptly stop taking duloxetine without speaking with their prescribing doctor or pharmacist. Suddenly stopping duloxetine can cause withdrawal symptoms, worsening depression, anxiety, dizziness, nausea, headache, irritability, sleep disruption, and other complications. Patients should first confirm whether their prescription came from an affected lot and then obtain medical guidance about replacement medication or a safe treatment plan.

What Is Duloxetine And Why Is It Prescribed?

Duloxetine is a serotonin-norepinephrine reuptake inhibitor, commonly called an SNRI. It works by affecting brain chemicals involved in mood regulation and pain signaling. Many patients take duloxetine every day for major depressive disorder, generalized anxiety disorder, fibromyalgia, diabetic peripheral neuropathy, chronic musculoskeletal pain, and other physician-approved uses.

Because duloxetine is frequently prescribed for long-term use, contamination concerns are especially important. A short medication exposure may present a different risk profile than taking a contaminated prescription for months or years. When patients take a medication daily, even small impurities can become more concerning if levels exceed FDA-recommended intake limits.

For many patients, duloxetine is not optional in a practical sense. It may be part of a long-standing treatment plan used to manage mental health symptoms, nerve pain, or chronic pain. That is why prescription drug recalls require careful handling. Patients need to protect themselves from potential contamination risks while also avoiding the health risks that can occur when medication is stopped too quickly.

What Are Nitrosamines?

Nitrosamines are chemical impurities that can form during drug manufacturing, storage, packaging, or degradation. They are also found at low levels in some foods and water. The issue is not that every trace exposure automatically causes harm. The concern is prolonged exposure above acceptable daily limits.

The FDA has been investigating nitrosamine impurities in medications for several years. Similar concerns have affected blood pressure drugs, diabetes medications, heartburn medications, smoking cessation medications, and other drug products. These recalls often involve questions about manufacturing controls, chemical stability, testing procedures, and whether companies identified and corrected contamination risks quickly enough.

N-nitroso-duloxetine is considered a nitrosamine drug substance-related impurity because it is related to the duloxetine drug substance itself. These impurities can be difficult to manage because they may form based on the chemical structure of the medication, manufacturing process, storage conditions, or packaging environment.

Drug manufacturers are responsible for testing their products, understanding their manufacturing processes, controlling impurities, and ensuring medications remain within acceptable safety limits throughout their shelf life.

Affected Duloxetine Products

Patients should check their prescription bottle, pharmacy records, and manufacturer information to determine whether their medication may be included in the recall. The recall reportedly affects specific lots of duloxetine delayed-release capsules distributed by Breckenridge Pharmaceutical.

Affected products include certain:

• 30 mg duloxetine delayed-release capsules in 1,000-count bottles
• 60 mg duloxetine delayed-release capsules in 90-count and 1,000-count bottles

Reported affected lot information includes:

• 30 mg duloxetine delayed-release capsules, lot 241180C, expiration April 2027
• 60 mg duloxetine delayed-release capsules with multiple affected lots and expiration dates ranging from November 2026 through May 2027

Because pharmacies often repackage medication from large bottles into smaller patient prescription bottles, patients may not see the original manufacturer’s bottle. If the lot number is not visible on the prescription container, patients should call their pharmacy and ask whether their prescription was filled from a recalled lot.

Patients should keep their bottle, pharmacy paperwork, refill history, and any recall notices they receive. These records may become important if a legal claim is later reviewed.

Why This Recall Matters For Patients

A prescription drug recall involving a potential carcinogenic impurity can cause immediate fear, especially for patients who have taken the medication for a long time. While the FDA has explained that low-level nitrosamine exposure is common and does not automatically mean someone will develop cancer, the agency sets acceptable intake limits for a reason.

When a drug contains nitrosamine levels above the recommended limit, the concern is cumulative exposure. Patients who took affected duloxetine capsules over an extended period may worry about what their exposure means for their future health.

Important questions may include:

• How long was the recalled medication taken?
• What dosage was prescribed?
• Was the patient exposed to multiple recalled lots?
• Did the patient have other cancer risk factors?
• Has the patient developed cancer or abnormal medical findings?
• Did the manufacturer or distributor act quickly after discovering the issue?
• Did patients receive timely notice?

These questions matter in both medical and legal evaluations.

Potential Legal Claims Involving Recalled Duloxetine

Prescription drug contamination cases may involve product liability claims against manufacturers, distributors, or other entities in the supply chain. Legal claims may focus on whether the companies responsible for the medication failed to properly test, manufacture, monitor, or warn consumers about contamination risks.

Potential claims may include defective manufacturing, failure to warn, negligence, breach of warranty, and failure to follow proper quality control procedures. If patients develop cancer or other serious medical conditions after long-term exposure to recalled medication, attorneys may investigate whether the illness may be connected to the contamination.

These cases are often complex because proving injury requires more than showing that a recalled medication was taken. Attorneys may need pharmacy records, lot information, duration of use, medical history, cancer diagnosis records, pathology reports, and scientific evidence regarding nitrosamine exposure.

Even patients who have not been diagnosed with cancer may want to preserve evidence and monitor developments. Some drug contamination cases involve medical monitoring claims, refund claims, or other forms of legal relief, depending on the facts and jurisdiction.

What Patients Should Do Now

Patients who believe they may have recalled duloxetine should not panic and should not stop the medication suddenly. The first step is to contact the pharmacy that filled the prescription and ask whether the medication came from an affected lot. Patients should also speak with their prescribing doctor about whether they need a replacement prescription or alternative medication.

Patients should preserve:

• Prescription bottles
• Pharmacy receipts
• Refill records
• Lot information
• Recall notices
• Medical records
• Notes about when the medication was taken
• Any cancer diagnosis or abnormal testing records

Patients should also report adverse events or product quality concerns through FDA MedWatch. Reporting helps regulators identify patterns and assess the full scope of potential harm.

Contact Parker Waichman LLP For A Free Duloxetine Recall Consultation

If you or a loved one took recalled duloxetine delayed-release capsules and later developed cancer or another serious medical condition, you may have legal rights. Parker Waichman LLP is reviewing potential claims involving recalled generic Cymbalta products contaminated with N-nitroso-duloxetine.

Our national product liability attorneys represent injured consumers in dangerous drug and defective product cases across the United States. We can help review prescription records, pharmacy information, recall details, medical history, and potential legal claims.

For a free consultation, call Parker Waichman LLP today at 1-800-YOUR-LAWYER (1-800-968-7529). Regardless of your location or where your injury occurred, our nationwide product injury law firm is ready to assist you.

There are no fees unless we recover compensation for you.